title: [Pharmacokinetics of ginkgolides sustained-release tablet].
abstract: OBJECTIVE
  To study the pharmacokinetics and bioavailability of ginkgolides sustained-release tablet and conventional tablet in Beagle dogs.
  
  
  METHODS
  The concentrations of ginkgolides in plasma were determined by LC-MS. The main pharmacokinetic parameters of ginkgolides sustained-release tablet and conventional tablet in vivo were obtained using Pharmacokinetic software DAS 2.0.
  
  
  RESULTS
  The C(max) of grinkgolide A in ginkgolide sustained-release tablet and conventional tablet were 443.51, 1 039.30 microg x L(-1), respecitvely. t(max) were 2.92, 1.08 h, respectively. AUC(0-12h) were 1 808.21, 2 041.37 h x microg(-1) x L(-1), respectively. MRT were 5.18, 3.18 h, respectively. The relative bioavailability of ginkgolides A was 88.58%. The C(max) of ginkgolide B in ginkgolide sustained-release tablet and conventional tablet were 407.13, 547.38 microg x L(-1), respectively. t(max) were 2.92, 1.08 h, respectively. AUC(01-12 h) were 1 987.31, 1 748.04 h x microg(-1) x L(-1), respectively. MRT were 6.05, 4.98 h, respectively. The relative bioavailability of ginkgolides B was 113.69%.
  
  
  CONCLUSIONS
  The ginkgolides sustained-release tablets have good sustained release characteristics and are bioequivalent to the reference formulation.
authors.affiliation: Nanjing University of Traditional Chinese Medicine, Nanjing 210046, China. may-850530@163.com
authors.forename: Miaomiao
authors.initials: M
authors.lastname: Jin
authors.forename: Qingming
authors.initials: Q
authors.lastname: Guo
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Sun
authors.forename: Xuan
authors.initials: X
authors.lastname: Zhang
authors.forename: Yaozhong
authors.initials: Y
authors.lastname: Lv
authors.forename: Wei
authors.initials: W
authors.lastname: Xiao
mesh_terms: D000818:Animals; D019540:Area Under Curve; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics; D004285:Dogs; D046934:Ginkgolides / Q000008:administration & dosage* / Q000032:analysis / Q000493:pharmacokinetics*; D007783:Lactones / Q000032:analysis*; D008297:Male; D013058:Mass Spectrometry / Q000379:methods; D011786:Quality Control; D013607:Tablets / Q000008:administration & dosage / Q000493:pharmacokinetics; D013810:Therapeutic Equivalency
chemical_list: D003692:Delayed-Action Preparations; D046934:Ginkgolides; D007783:Lactones; D013607:Tablets; C045856:ginkgolide B; C477042:ginkgolide A